Trials / Completed
CompletedNCT06199505
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
A Phase II Trial Comparing Efficacy and Safety of GZR101 and Insulin Degludec/Insulin Aspart in Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drug (OAD) Therapy or OAD Therapy in Combination with Insulin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Gan and Lee Pharmaceuticals, USA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in China. The aim of the trial is to compare the efficacy and safety of GZR101 and insulin degludec/insulin aspart in insulin naïve or insulin treated subjects with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR101 | Once daily |
| DRUG | insulin degledec/insulin aspart | Once daily or twice daily |
Timeline
- Start date
- 2023-11-21
- Primary completion
- 2024-06-28
- Completion
- 2024-07-12
- First posted
- 2024-01-10
- Last updated
- 2025-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06199505. Inclusion in this directory is not an endorsement.